Pyros Pharmaceuticals is a specialty pharmaceutical company focused on developing medicines for rare pediatric diseases and underserved patient populations. We explore a broad range of therapeutic areas that have technically challenging drug delivery mechanisms or other niche applications. Our goal is to provide high-quality, affordable and accessible alternatives for patients that need them the most.

Director / Sr. Director, Medical Affairs

Key Account Manager - Boston, MA

Key Account Manager - Memphis, TN

Pyros Pharmaceuticals

Regulatory Affairs CMC Manager

Regulatory Affairs Specialist

Regulatory Affairs

Senior Manager, Quality Operations

Senior Director Quality Assurance

Senior Manager Quality Assurance

Sr Director, Medical Affairs

Senior Medical Director, Neuroscience

Global Medical Lead, Neuroscience

Senior Director, Medical Affairs

Director, Medical Affairs

Director, Medical Science Liaisons

Director, Medical Sciences

Product Development Scientific Director - Medical Affairs

Sales Director, Managed Care

Medical Information Scientist - Medical Affairs

Regional Director, Pharmacy

Assistant Vice President / Operations

Director, Pharmacy and IV Therapy

Manager, Quality and Compliance

Quality Compliance Auditor

Quality Assurance Manager

Quality Compliance Lead

Quality and Regulatory Analyst

Chemist

Senior Review Chemist

Review Chemist

Cloudflare DNS

Rackspace MailGun

Gmail

Outlook

Google Apps

CloudFlare Hosting

Co-Founder

Turing Pharmaceuticals AG is a privately-held biopharmaceutical company with offices in New York City and Zug, Switzerland. Turing focuses on developing and commercializing innovative treatments for serious diseases and conditions across a broad range of therapeutic areas, for which there are currently limited or no treatment options. Products being developed include intranasal ketamine for a variety of disorders and Syntocinon® (oxytocin nasal solution) for multiple indications. Vecamyl® (mecamylamine HCl tablets) is Turing's first commercial product. On August 10, 2015, the company announced the acquisition of Daraprim® from Impax Laboratories, Inc.

Turing Pharmaceuticals AG

Clerical Officer

Key Account Manager

Executive Hospital Representative

Senior Hospital Account Specialist

At Retrophin, our number one priority will always be the patients we serve – they are "why" we come to work each day.  Our Why is ingrained into our culture and is paramount to "what" we do every day and "how" we do it to achieve our mission of identifying, developing and delivering life-changing therapies to people living with rare disease. By working hard, supporting our team members and living our values of Accountability, Entrepreneurial Spirit, Integrity, Patient Focus, Scientific Excellence and Teamwork, we strive to help our organization succeed and pursue our vision – to become a preeminent, global and fully-integrated biopharmaceutical company within the rare disease=community that is dedicated to giving patients a chance and providing hope. Our pipeline features late-stage development programs targeting rare diseases with significant unmet medical needs including sparsentan for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease. In partnership with leaders in patient advocacy and government research, we are also working to identify potential therapeutics for NGLY1 deficiency and Alagille syndrome, conditions with no approved treatment options. Our R&D efforts are supported by revenues from our four commercial products Chenodal® (chenodiol), Cholbam® (cholic acid), Thiola® (tiopronin) and THIOLA EC™ (tiopronin) delayed-release tablets. Through our portfolio of approved products and promising pipeline focused on hepatology and nephrology, we strive to help people achieve the best possible outcomes today and tomorrow. But most importantly, it is the commitment of our experienced, knowledgeable and compassionate team members, who put patients at the center of everything they do, that truly matters.Please read our community guidelines to understand how we manage our social media engagement: retrophin.com/community-guidelines

Retrophin

Mimecast

Microsoft Office 365

Amazon AWS

accessiBe

Vice President of Finance

Analyst

The Swiss Re Group is a leading wholesale provider of reinsurance, insurance and other insurance-based forms of risk transfer. Dealing direct and working through brokers, its global client base consists of insurance companies, mid-to-large-sized corporations and public sector clients. From standard products to tailor-made coverage across all lines of business, Swiss Re deploys its capital strength, expertise and innovation power to enable the risk taking upon which enterprise and progress in society depend. Founded in Zurich, Switzerland, in 1863, Swiss Re serves clients through a network of over 70 offices globally and is rated "AA-"​ by Standard & Poor's, "Aa3"​ by Moody's and "A+"​ by A.M. Best. Registered shares in the Swiss Re Group holding company, Swiss Re Ltd, are listed in accordance with the Main Standard on the SIX Swiss Exchange and trade under the symbol SREN. We're smarter together.For more information about Swiss Re Group, please visit: www.swissre.com, follow us on X @SwissRe and subscribe our YouTube channel @swissretv.

Underwriting Associate

Internal Consultant in L&H Reinsurance - Hybrid

Senior Risk Consultant (Hybrid, 80 - 100%, m/f/x/d)

Underwriting Assistant- General Property

Swiss Re

SuccessFactors (SAP)

Zendesk

Banco Santander (SAN SM, STD US, BNC LN) is a leading commercial bank, founded in 1857 and headquartered in Spain. It has a meaningful presence in 10 core markets in the Europe, North America and South America regions, and is one of the largest banks in the world by market capitalization. Santander aims to be the best open financial services platform providing services to individuals, SMEs, corporates, financial institutions and governments. The bank's purpose is to help people and businesses prosper in a simple, personal and fair way. Santander is building a more responsible bank and has made a number of commitments to support this objective, including raising €220 billion in green financing between 2019 and 2030. At the end of 2023, Banco Santander had €1.3 trillion in total funds, 165 million customers, 8,500 branches and over 212,000 employees.

Edwin Urrutia

Co-Founder at Pyros Pharmaceuticals

Edwin Urrutia's Professional Contact Details

Edwin Urrutia's Current Company Details

Pyros Pharmaceuticals

Edwin Urrutia's Work History and Education

Others Named Edwin Urrutia

Frequently Asked Questions about Edwin Urrutia

What company does Edwin Urrutia work for?

What is Edwin Urrutia's role at Pyros Pharmaceuticals?

What is Edwin Urrutia's email address?

What is Edwin Urrutia's business email address?

What industry does Edwin Urrutia work in?

Who are Edwin Urrutia's colleagues?

Colleagues at Pyros Pharmaceuticals

Prospect on LinkedIn

People Search

Company Search

Erik Straub

Michael Transon

Ready to try it out?